Zobrazeno 1 - 10 of 15 pro vyhledávání: '"Aaron, Schetter"'
1
Akademický článek
A small protein encoded by a putative lncRNA regulates apoptosis and tumorigenicity in human colorectal cancer cells
Autor: Xiao Ling Li, Lőrinc Pongor, Wei Tang, Sudipto Das, Bruna R Muys, Matthew F Jones, Sarah B Lazar, Emily A Dangelmaier, Corrine CR Hartford, Ioannis Grammatikakis, Qinyu Hao, Qinyu Sun, Aaron Schetter, Jennifer L Martindale, BinWu Tang, Lisa M Jenkins, Ana I Robles, Robert L Walker, Stefan Ambs, Raj Chari, Svetlana A Shabalina, Myriam Gorospe, S Perwez Hussain, Curtis C Harris, Paul S Meltzer, Kannanganattu V Prasanth, Mirit I Aladjem, Thorkell Andresson, Ashish Lal
Publikováno v: eLife, Vol 9 (2020)
Long noncoding RNAs (lncRNAs) are often associated with polysomes, indicating coding potential. However, only a handful of endogenous proteins encoded by putative lncRNAs have been identified and assigned a function. Here, we report the discovery of
Externí odkaz: https://doaj.org/article/c60bfdd56a884b3f80b57d44916ac23e
Zobrazit plný text záznamu
2
Akademický článek
Long Noncoding RNA PURPL Suppresses Basal p53 Levels and Promotes Tumorigenicity in Colorectal Cancer
Autor: Xiao Ling Li, Murugan Subramanian, Matthew F. Jones, Ritu Chaudhary, Deepak K. Singh, Xinying Zong, Berkley Gryder, Sivasish Sindri, Min Mo, Aaron Schetter, Xinyu Wen, Swetha Parvathaneni, Dickran Kazandjian, Lisa M. Jenkins, Wei Tang, Fathi Elloumi, Jennifer L. Martindale, Maite Huarte, Yuelin Zhu, Ana I. Robles, Susan M. Frier, Frank Rigo, Maggie Cam, Stefan Ambs, Sudha Sharma, Curtis C. Harris, Mary Dasso, Kannanganattu V. Prasanth, Ashish Lal
Publikováno v: Cell Reports, Vol 20, Iss 10, Pp 2408-2423 (2017)
Basal p53 levels are tightly suppressed under normal conditions. Disrupting this regulation results in elevated p53 levels to induce cell cycle arrest, apoptosis, and tumor suppression. Here, we report the suppression of basal p53 levels by a nuclear
Externí odkaz: https://doaj.org/article/44875ca0858a47c68888951b9611cf2c
Zobrazit plný text záznamu
4
Data from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
Autor: Richard Pazdur, Ann T. Farrell, Reena Philip, Albert Deisseroth, Rajeshwari Sridhara, Donna Roscoe, Yuan Li Shen, Donna Przepiorka, Aaron Schetter, Qing Xu, Emily Y. Jen
On March 29, 2018, the FDA granted accelerated approval for blinatumomab (Blincyto; Amgen, Inc.) for the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia (BCP ALL) in first or second complete remission with minimal
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4633f148f2828c48b9597e5e86f99f2c
https://doi.org/10.1158/1078-0432.c.6528714
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje